Bioleaders Corporation (142760) — Cash Flow-to-Debt Ratio
Bioleaders Corporation (142760) has a Cash Flow-to-Debt Ratio of -0.10x as of December 2025, meaning its operating cash flow of ₩-1.26 Billion could theoretically repay 0% of its total liabilities (₩12.04 Billion) in one year. See how much free cash does Bioleaders Corporation generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Bioleaders Corporation Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Bioleaders Corporation across 11 annual periods. Also explore Bioleaders Corporation (142760) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Bioleaders Corporation (2015–2025)
Year-by-year debt coverage analysis for Bioleaders Corporation. For market capitalisation and broader financial context, see Bioleaders Corporation (142760) total market value.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.50x | ₩-5.97 Billion | ₩12.04 Billion | ▼ -2364.8% |
| 2024 | -0.02x | ₩-501.75 Million | ₩24.94 Billion | ▼ -104.3% |
| 2023 | 0.47x | ₩6.18 Billion | ₩13.28 Billion | ▲ +386.1% |
| 2022 | -0.16x | ₩-20.60 Billion | ₩126.73 Billion | ▼ -364.0% |
| 2021 | -0.04x | ₩-5.04 Billion | ₩143.74 Billion | ▼ -3.4% |
| 2020 | -0.03x | ₩-5.43 Billion | ₩160.09 Billion | ▼ -91.9% |
| 2019 | -0.02x | ₩-2.20 Billion | ₩124.30 Billion | ▲ +73.9% |
| 2018 | -0.07x | ₩-8.77 Billion | ₩129.79 Billion | ▲ +98.1% |
| 2017 | -3.54x | ₩-8.53 Billion | ₩2.41 Billion | ▼ -90.7% |
| 2016 | -1.85x | ₩-7.70 Billion | ₩4.15 Billion | ▼ -53.1% |
| 2015 | -1.21x | ₩-4.83 Billion | ₩3.99 Billion | — |